AS 35;3-(1H-Tetrazol-5-yl)-9-[[[2-propyl-3-hydroxy-4-(methylcarbonyl)phenyl]oxy]methyl]-4H-pyrido[1,2-a]pyrimidin-4-one;4H-Pyrido[1,2-a]pyrimidin-4-one, 9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)-;AS 35,AS35
AS-35 is an effective, orally active, and selective leukotriene antagonist with anti-allergic properties. It inhibits LTC4-, LTD4-, and LTE4-induced ileal contractions in isolated guinea pig ileum with IC50 values of 8 nM, 4 nM, and 3 nM, respectively. In the trachea, it antagonizes LTD4- and LTE4-induced contractions with IC50 values of 10 nM and 20 nM, respectively. In vivo, AS-35 dose-dependently antagonizes LTC4- and LTD4-induced bronchoconstriction in anesthetized guinea pigs following intravenous administration (0.0375–0.3 mg/kg), but does not inhibit histamine-induced bronchoconstriction. Orally administered AS-35 also antagonizes LTD4- and antigen-induced, leukotriene-mediated bronchoconstriction and inhibits LTD4-induced increases in cutaneous vascular permeability in guinea pigs.